Immune Globulin Articles
Less-common adverse reactions to IG therapy are rare, but they are more severe.
Thirty years after its quiet introduction, unabated global research interest in IVIG reflects just how much remains unknown about its therapeutic potential.
Attention to meeting payer requirements is good for the bottom line.
While all IG products are comparably effective, they also have relevant differences that determine their tolerability by patients.
